GeoVax Labs (GOVX) Expected to Post Earnings on Thursday

GeoVax Labs (NASDAQ:GOVX) will likely be announcing its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to announce earnings of ($1.09) per share for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:30 PM ET.

GeoVax Labs Stock Performance

Shares of NASDAQ GOVX opened at $0.14 on Tuesday. The firm has a market capitalization of $1.05 million, a P/E ratio of -0.01 and a beta of 3.85. GeoVax Labs has a one year low of $0.14 and a one year high of $13.00. The company’s fifty day moving average is $0.32 and its two-hundred day moving average is $1.19.

Wall Street Analyst Weigh In

GOVX has been the subject of a number of research analyst reports. Noble Financial reiterated an “outperform” rating on shares of GeoVax Labs in a report on Tuesday, September 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Thursday, October 15th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, GeoVax Labs presently has an average rating of “Hold” and an average target price of $150.00.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses.

GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.